U.S. markets closed

Lantheus Holdings, Inc. (LNTH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
18.68-0.47 (-2.45%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close19.15
Bid16.50 x 800
Ask18.68 x 800
Day's Range17.27 - 19.15
52 Week Range8.67 - 20.29
Avg. Volume553,642
Market Cap1.249B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-21% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Lantheus Holdings Inc (LNTH) Q4 2020 Earnings Call Transcript
    Motley Fool

    Lantheus Holdings Inc (LNTH) Q4 2020 Earnings Call Transcript

    LNTH earnings call for the period ending December 31, 2020.

  • Benzinga

    Recap: Lantheus Holdings Q4 Earnings

    Shares of Lantheus Holdings (NASDAQ:LNTH) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 79.41% year over year to $0.07, which beat the estimate of $0.01. Revenue of $94,152,000 up by 5.38% year over year, which beat the estimate of $92,230,000. Guidance The upcoming fiscal year's EPS expected to be between $0.34 and $0.39. The upcoming fiscal year's revenue expected to be between $385,000,000 and $400,000,000. Details Of The Call Date: Feb 25, 2021 View more earnings on LNTH Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/fnf394tc Recent Stock Performance Company's 52-week high was at $20.29 52-week low: $8.67 Price action over last quarter: Up 69.92% Company Profile Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacy and directly to hospitals and clinics predominantly in the United States. See more from BenzingaClick here for options trades from BenzingaSTORE Capital: Q4 Earnings Insights12 Information Technology Stocks Moving In Thursday's After-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
    Business Wire

    Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results

    Lantheus Holdings, Inc. (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, today reported financial results for its fourth quarter and full year ended December 31, 2020.